{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:04:39Z","timestamp":1789787079076,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["Dekkerbeurs 03-005-2021-T005"],"award-info":[{"award-number":["Dekkerbeurs 03-005-2021-T005"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Junior Scientific Masterclass","award":["MA 20-04"],"award-info":[{"award-number":["MA 20-04"]}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC CoG 818715"],"award-info":[{"award-number":["ERC CoG 818715"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["SECRETE-HF"],"award-info":[{"award-number":["SECRETE-HF"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Immune checkpoint inhibitors (ICIs) have improved the field of cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular immune-related adverse events (irAEs) with high mortality and morbidity have been observed, including myocarditis, pericarditis, and vasculitis. To date, only a few clinical risk factors have been described and are currently being investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>In this review, we address the four most prevailing risk factors for cardiovascular irAEs. ICI combination therapy is a predominant risk factor for developing ICI-mediated myocarditis. Additionally, ICI combined with other anti-cancer treatments (e.g., tyrosine kinase inhibitors, radiation, chemotherapy) seems to increase the risk of developing cardiovascular irAEs. Other risk factors include female sex, pre-existing cardiovascular disease, and specific tumors, on which we will further elaborate in this review.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>An a priori risk strategy to determine who is at risk to develop these cardiovascular irAEs is needed. Insights into the impact of risk factors are therefore warranted to help clinicians improve care and disease management in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-023-01414-4","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T12:22:16Z","timestamp":1681993336000},"page":"753-763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Risk Factors for Immune Checkpoint Inhibitor\u2013Mediated Cardiovascular Toxicities"],"prefix":"10.1007","volume":"25","author":[{"given":"Laura I.","family":"Yousif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elles M.","family":"Screever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00eblle","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Pierre","family":"Aboumsallem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier C.","family":"Manintveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"412","key":"1414_CR1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(412):252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1414_CR2","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"1414_CR3","first-page":"537","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. Faculty Sci Med Health - Papers: Part B. 2019;37:537.","journal-title":"Faculty Sci Med Health - Papers: Part B"},{"key":"1414_CR4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721\u20138.","journal-title":"JAMA Oncol"},{"key":"1414_CR5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"key":"1414_CR6","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"1414_CR7","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","volume":"123","author":"DB Johnson","year":"2017","unstructured":"Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904\u201311.","journal-title":"Cancer"},{"key":"1414_CR8","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.3389\/fphar.2022.989431","volume":"13","author":"LI Yousif","year":"2022","unstructured":"Yousif LI, Tanja AA, de Boer RA, Teske AJ, Meijers WC. The role of immune checkpoints in cardiovascular disease. Front Pharmacol. 2022;13:4065.","journal-title":"Front Pharmacol"},{"key":"1414_CR9","doi-asserted-by":"crossref","first-page":"E008563","DOI":"10.1161\/CIRCHEARTFAILURE.121.008563","volume":"14","author":"A Choudhary","year":"2021","unstructured":"Choudhary A, Brinkley DM, Besharati S, et al. PD-L1 (programmed death ligand 1) as a marker of acute cellular rejection after heart transplantation. Circ Heart Fail. 2021;14:E008563.","journal-title":"Circ Heart Fail"},{"key":"1414_CR10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.7150\/jca.49174","volume":"12","author":"X Ma","year":"2021","unstructured":"Ma X, Zhang Y, Wang S, Wei H, Yu J. Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: a systematic review. J Cancer. 2021;12:1318.","journal-title":"J Cancer"},{"key":"1414_CR11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"1414_CR12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","volume":"24","author":"TS Nowicki","year":"2018","unstructured":"Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 2018;24:47.","journal-title":"Cancer J"},{"key":"1414_CR13","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"\u2022 Rubio-Infante N, Ram\u00edrez-Flores YA, Castillo EC, Lozano O, Garc\u00eda-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23:1739\u201347. This meta-analysis highlights the increased incidence of ICI-mediated cardiotoxicity as a result of dual ICI therapy or combining ICI therapy with other anti-cancer treatments.","journal-title":"Eur J Heart Fail"},{"key":"1414_CR14","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"},{"key":"1414_CR15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","volume":"208","author":"T Okazaki","year":"2011","unstructured":"Okazaki T, Okazaki IM, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208:395.","journal-title":"J Exp Med"},{"key":"1414_CR16","first-page":"917","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917\u201327.","journal-title":"Cancer Res"},{"key":"1414_CR17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"\u2022\u2022 Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24\u201334. This phase 2\u20133 clinical trial demonstrated, for the first time, the synergtistic anti-tumor activity of combined nivolumab and relatlimab, the first-in-class human LAG-3 inhibitor. Myocarditis incidence was nearly threefold in the combined group compared to the nivolumab monotherapy group, resulting in one death.","journal-title":"N Engl J Med"},{"key":"1414_CR18","doi-asserted-by":"crossref","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","volume":"9","author":"J Gong","year":"2021","unstructured":"Gong J, Drobni ZD, Zafar A, et al. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9:e002771.","journal-title":"J Immunother Cancer"},{"key":"1414_CR19","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.3390\/ijms231810948","volume":"23","author":"A Cozma","year":"2022","unstructured":"Cozma A, Sporis ND, Lazar AL, et al. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Int J Mol Sci. 2022;23:10948.","journal-title":"Int J Mol Sci"},{"key":"1414_CR20","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.jaccas.2020.07.028","volume":"2","author":"H Oishi","year":"2020","unstructured":"Oishi H, Morimoto R, Shimoyama Y, Kuroda K, Urata T, Kondo T, Okumura T, Bando YK, Akiyama M, Murohara T. Myocardial vasculitis associated with the immune checkpoint inhibitor pembrolizumab. JACC Case Rep. 2020;2:1937.","journal-title":"JACC Case Rep"},{"key":"1414_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2021.663088\/PDF","author":"Z Ma","year":"2021","unstructured":"Ma Z, Pei J, Sun X, Liu L, Lu W, Guo Q, Lyu J, Liu Y, Zhang Y, Zhao Z. Pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/FPHAR.2021.663088\/PDF.","journal-title":"Front Pharmacol"},{"key":"1414_CR22","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115:854\u201368.","journal-title":"Cardiovasc Res"},{"key":"1414_CR23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989.","journal-title":"Immunity"},{"key":"1414_CR24","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187\u201394.","journal-title":"J Exp Med"},{"key":"1414_CR25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00262-021-02974-9","volume":"71","author":"S Mao","year":"2022","unstructured":"Mao S, Zhou F, Liu Y, et al. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. Cancer Immunol Immunother. 2022;71:219\u201328.","journal-title":"Cancer Immunol Immunother"},{"key":"1414_CR26","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer. N Engl J Med. 2018;379:2040\u201351.","journal-title":"N Engl J Med"},{"key":"1414_CR27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18:895\u2013903.","journal-title":"Lancet Oncol"},{"key":"1414_CR28","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1158\/1078-0432.CCR-22-1687","volume":"28","author":"Y Taniguchi","year":"2022","unstructured":"Taniguchi Y, Shimokawa T, Takiguchi Y, et al. A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-na\u00efve non-small-cell lung cancer: TORG1630. Clin Cancer Res. 2022;28:4402\u20139.","journal-title":"Clin Cancer Res"},{"key":"1414_CR29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","volume":"13","author":"S Du","year":"2018","unstructured":"Du S, Zhou L, Alexander GS, et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol. 2018;13:510\u201320.","journal-title":"J Thorac Oncol"},{"key":"1414_CR30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ijrobp.2017.06.2452","volume":"99","author":"CJ Myers","year":"2017","unstructured":"Myers CJ, Lu B. Decreased survival after combining thoracic irradiation and an anti-PD-1 antibody is correlated with increased T cell infiltration into cardiac and lung tissues. Int J Radiat Oncol Biol Phys. 2017;99:1129.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1414_CR31","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.2019.17415","volume":"322","author":"WC Meijers","year":"2019","unstructured":"Meijers WC, Moslehi JJ. Need for multidisciplinary research and data-driven guidelines for the cardiovascular care of patients with cancer. JAMA. 2019;322:1775\u20136.","journal-title":"JAMA"},{"key":"1414_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02402-z","volume":"22","author":"XT Zhang","year":"2022","unstructured":"Zhang XT, Ge N, Xiang ZJ, Liu T. Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. Cancer Cell Int. 2022;22:1\u201312.","journal-title":"Cancer Cell Int"},{"key":"1414_CR33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.lungcan.2020.10.017","volume":"150","author":"R Bishnoi","year":"2020","unstructured":"Bishnoi R, Shah C, Blaes A, Bian J, Hong Y-R. Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: a SEER-medicare study CVD outcomes with the use of ICI in mNSCLC. Lung Cancer. 2020;150:172\u20137.","journal-title":"Lung Cancer"},{"issue":"1","key":"1414_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-96467-5","volume":"11","author":"T Makunts","year":"2021","unstructured":"Makunts T, Saunders IM, Cohen IV, Li M, Moumedjian T, Issa MA, Burkhart K, Lee P, Patel SP, Abagyan R. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Scientific Reports. 2021;11(1):1\u201315.","journal-title":"Scientific Reports"},{"key":"1414_CR35","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","volume":"115","author":"WC Meijers","year":"2019","unstructured":"Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019;115:844\u201353.","journal-title":"Cardiovasc Res"},{"key":"1414_CR36","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103\u201315.","journal-title":"N Engl J Med"},{"key":"1414_CR37","doi-asserted-by":"crossref","unstructured":"Jain V, Mohebtash M, Rodrigo M, \u2026 GR-J of, 2018 undefined Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. journals.lww.com","DOI":"10.1097\/CJI.0000000000000239"},{"key":"1414_CR38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.annonc.2020.10.481","volume":"32","author":"L Meza","year":"2021","unstructured":"Meza L, Bergerot PG, Agarwal N, Pal SK. Is there a role for novel TKI\/ICI combinations in metastatic renal cell carcinoma? Definitely maybe. Ann Oncol. 2021;32:12\u20134.","journal-title":"Ann Oncol"},{"key":"1414_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14051145\/S1","author":"C Li","year":"2022","unstructured":"Li C, Bhatti SA, Ying J. Immune checkpoint inhibitors\u2014associated cardiotoxicity. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/CANCERS14051145\/S1.","journal-title":"Cancers (Basel)"},{"key":"1414_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/S40959-022-00130-5","author":"ZL Brumberger","year":"2022","unstructured":"Brumberger ZL, Branch ME, Klein MW, Seals A, Shapiro MD, Vasu S. Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardiooncology. 2022. https:\/\/doi.org\/10.1186\/S40959-022-00130-5.","journal-title":"Cardiooncology"},{"key":"1414_CR41","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","volume":"125","author":"O Oren","year":"2020","unstructured":"Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors. Am J Cardiol. 2020;125:1920\u20136.","journal-title":"Am J Cardiol"},{"key":"1414_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13205218","author":"W Shalata","year":"2021","unstructured":"Shalata W, Abu-salman A, Steckbeck R, Jacob BM, Massalha I, Yakobson A. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/CANCERS13205218.","journal-title":"Cancers (Basel)"},{"key":"1414_CR43","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377\u201385.","journal-title":"Ann Oncol"},{"key":"1414_CR44","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jamaoncol.2019.3221","volume":"5","author":"D Bomze","year":"2019","unstructured":"Bomze D, Hasan Ali O, Bate A, Flatz L. Association between immune-related adverse events during anti\u2013PD-1 therapy and tumor mutational burden. JAMA Oncol. 2019;5:1633\u20135.","journal-title":"JAMA Oncol"},{"key":"1414_CR45","doi-asserted-by":"publisher","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. (2020) https:\/\/doi.org\/10.1186\/S12916-020-01549-2","DOI":"10.1186\/S12916-020-01549-2"},{"key":"1414_CR46","first-page":"3723","volume":"11","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Wang X, Qu J, Zuo W, Tang Y, Zhu H, Chen X. Immune-related adverse events associated with outcomes in patients with NSCLC treated with nti-PD-1 inhibitors: a systematic review and meta-analysis. Front Oncol. 2021;11:3723.","journal-title":"Front Oncol"},{"key":"1414_CR47","doi-asserted-by":"crossref","first-page":"355.e21","DOI":"10.1016\/j.urolonc.2019.03.003","volume":"37","author":"H Ishihara","year":"2019","unstructured":"Ishihara H, Takagi T, Kondo T, et al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urologic Oncology: Seminars and Original Investigations. 2019;37:355.e21-355.e29.","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"1414_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/VACCINES10040540","author":"D Ronen","year":"2022","unstructured":"Ronen D, Bsoul A, Lotem M, Abedat S, Yarkoni M, Amir O, Asleh R. Exploring the mechanisms underlying the cardiotoxic effects of immune checkpoint inhibitor therapies. Vaccines (Basel). 2022. https:\/\/doi.org\/10.3390\/VACCINES10040540.","journal-title":"Vaccines (Basel)"},{"key":"1414_CR49","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","volume":"11","author":"SC Wei","year":"2021","unstructured":"Wei SC, Meijers WC, Axelrod ML, et al. A genetic mouse model recapitulates immune checkpoint inhibitor\u2013associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 2021;11:614\u201325.","journal-title":"Cancer Discov"},{"key":"1414_CR50","first-page":"1","volume":"2022","author":"ML Axelrod","year":"2022","unstructured":"\u2022 Axelrod ML, Meijers WC, Screever EM, et al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature. 2022;2022:1\u20139. Using a mouse model which recapitulates clinical ICI-mediated myocarditis, this article highlights the crucial role of CD8++ T cells and identifies \u03b1-myosin as a candidate self-antigen in ICI-mediated myocarditis. These findings demonstrate the important steps in translational research being taken in order to gain new insights into the pathogenises of ICI-mediated cardiotoxicity.","journal-title":"Nature"},{"key":"1414_CR51","doi-asserted-by":"crossref","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won T, Kalinoski HM, Wood MK, Hughes DM, Jaime CM, Delgado P, Talor MV, Lasrado N, Reddy J, \u010cih\u00e1kov\u00e1 D. Cardiac myosin-specific autoimmune T\u00a0cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 2022;41:111611.","journal-title":"Cell Rep"},{"key":"1414_CR52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.120360","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, Nixon MJ, Wang Y, et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3\/FCRL6 engagement. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.120360.","journal-title":"JCI Insight"},{"key":"1414_CR53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0065-2776(08)00604-4","volume":"99","author":"D Cihakova","year":"2008","unstructured":"Cihakova D, Rose NR. Chapter 4 Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol. 2008;99:95\u2013114.","journal-title":"Adv Immunol"},{"issue":"2","key":"1414_CR54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1684\/ejd.2021.4009","volume":"31","author":"C Scard","year":"2021","unstructured":"Scard C, Nguyen JM, Varey E, Moustaghfir I, Khammari A, Dreno B. Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma relevance of dosing troponin T levels. Eur J Dermatol. 2021;31(2):205\u201312.","journal-title":"Eur J Dermatol"},{"key":"1414_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/S40425-016-0152-Y","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016. https:\/\/doi.org\/10.1186\/S40425-016-0152-Y.","journal-title":"J Immunother Cancer"},{"key":"1414_CR56","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.3390\/cancers12113480","volume":"12","author":"R Noseda","year":"2020","unstructured":"Noseda R, Ruinelli L, van der Gaag LC, Ceschi A. Pre-existing cardiovascular conditions as clinical predictors of myocarditis reporting with immune checkpoint inhibitors: a VigiBase study. Cancers. 2020;12:3480.","journal-title":"Cancers"},{"key":"1414_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/S40959-022-00130-5","author":"ZL Brumberger","year":"2022","unstructured":"Brumberger ZL, Branch ME, Klein MW, Seals A, Shapiro MD, Vasu S. Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardiooncology. 2022. https:\/\/doi.org\/10.1186\/S40959-022-00130-5.","journal-title":"Cardiooncology"},{"key":"1414_CR58","first-page":"1192","volume":"9","author":"X Chen","year":"2022","unstructured":"Chen X, Jiang A, Zhang R, et al. Immune checkpoint inhibitor-associated cardiotoxicity in solid tumors: real-world incidence, risk factors, and prognostic analysis. Front Cardiovasc Med. 2022;9:1192.","journal-title":"Front Cardiovasc Med"},{"key":"1414_CR59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cpcardiol.2012.07.003","volume":"38","author":"DL Fairweather","year":"2013","unstructured":"Fairweather DL, Cooper LT, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38:7\u201346.","journal-title":"Curr Probl Cardiol"},{"key":"1414_CR60","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","volume":"37","author":"A Daxini","year":"2018","unstructured":"Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37:2579\u201384.","journal-title":"Clin Rheumatol"},{"key":"1414_CR61","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","volume":"5","author":"Y Zamami","year":"2019","unstructured":"Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, Ishizawa K. Factors associated with immune checkpoint inhibitor\u2013related myocarditis. JAMA Oncol. 2019;5:1635\u20137.","journal-title":"JAMA Oncol"},{"key":"1414_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.ABO1981","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Sun C, Li Y, et al. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med. 2022. https:\/\/doi.org\/10.1126\/SCITRANSLMED.ABO1981.","journal-title":"Sci Transl Med"},{"key":"1414_CR63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234\u201340.","journal-title":"JAMA Oncol"},{"key":"1414_CR64","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368\u201376.","journal-title":"Ann Oncol"},{"key":"1414_CR65","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Gainor JF, Altan M, et al. Safety of programmed death\u20131 pathway inhibitors among patients with non\u2013small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol. 2018;36:1905.","journal-title":"J Clin Oncol"},{"key":"1414_CR66","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447\u201358.","journal-title":"Lancet Oncol"},{"key":"1414_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-020-01431-w","volume":"23","author":"DJ Lee","year":"2021","unstructured":"Lee DJ, Lee HJ, Farmer JR, Reynolds KL. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Cardiol Rep. 2021;23:1\u201312.","journal-title":"Curr Cardiol Rep"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01414-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01414-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01414-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:15:36Z","timestamp":1686287736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01414-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01414-4","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"21 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}